Alex Mutebi

875 total citations
51 papers, 615 citations indexed

About

Alex Mutebi is a scholar working on Immunology, Political Science and International Relations and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alex Mutebi has authored 51 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 10 papers in Political Science and International Relations and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex Mutebi's work include Southeast Asian Sociopolitical Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Psoriasis: Treatment and Pathogenesis (7 papers). Alex Mutebi is often cited by papers focused on Southeast Asian Sociopolitical Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Psoriasis: Treatment and Pathogenesis (7 papers). Alex Mutebi collaborates with scholars based in United States, United Kingdom and Singapore. Alex Mutebi's co-authors include Anand A. Dalal, Annie Guérin, Kenneth W. Culver, Zheng‐Yi Zhou, Wenxi Tang, Gregory A. Otterson, Nathan A. Pennell, Medha Sasané, Bradley S. Stolshek and Kevin Y. Wu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Alex Mutebi

44 papers receiving 577 citations

Peers

Alex Mutebi
Pamela Church Gibson United States
Marjolaine Gauthier‐Loiselle United States
Robert C. Stuart United Kingdom
Richard M. Wolf United States
Adrienne Johnson United States
Jean Cuisenier France
Daniela Marconi Italy
Wojciech Woźniak Poland
Mark Napier United Kingdom
W. Andy Knight Canada
Pamela Church Gibson United States
Alex Mutebi
Citations per year, relative to Alex Mutebi Alex Mutebi (= 1×) peers Pamela Church Gibson

Countries citing papers authored by Alex Mutebi

Since Specialization
Citations

This map shows the geographic impact of Alex Mutebi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Mutebi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Mutebi more than expected).

Fields of papers citing papers by Alex Mutebi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Mutebi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Mutebi. The network helps show where Alex Mutebi may publish in the future.

Co-authorship network of co-authors of Alex Mutebi

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Mutebi. A scholar is included among the top collaborators of Alex Mutebi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Mutebi. Alex Mutebi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salles, Gilles, Christopher P. Fox, Mehdi Hamadani, et al.. (2025). Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). e986–e994.e4.
2.
Crombie, Jennifer L., et al.. (2023). REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL. Hematological Oncology. 41(S2). 719–720.
3.
Salles, Gilles, Christopher P. Fox, Anthony Wang, et al.. (2023). Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison. Blood. 142(Supplement 1). 1733–1733.
4.
Rosenthal, Allison, Javier Muñoz, Tongsheng Wang, et al.. (2023). P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS. HemaSphere. 7(S3). e9299527–e9299527.
5.
Thiéblemont, Catherine, Christopher P. Fox, Kavita Sail, et al.. (2023). Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect Comparison. Hematological Oncology. 41(S2). 453–454. 1 indexed citations
6.
Mahesri, Mufaddal, Sebastian Schneeweiß, Denise Globe, et al.. (2020). Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. European Journal Of Haematology. 106(2). 273–280. 7 indexed citations
7.
Desai, Rishi, Mufaddal Mahesri, Denise Globe, et al.. (2020). Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. Annals of Hematology. 99(11). 2497–2505. 18 indexed citations
8.
Matza, Louis S., John Brazier, Katie D. Stewart, et al.. (2019). Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). Journal of Medical Economics. 22(9). 936–944. 8 indexed citations
9.
Shadick, Nancy A., Nicole Gerlanc, Michelle Frits, et al.. (2019). The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry. Clinical Rheumatology. 38(11). 3081–3092. 5 indexed citations
10.
Stolshek, Bradley S., et al.. (2018). Two-year adherence and costs for biologic therapy for rheumatoid arthritis.. PubMed. 24(8 Spec No.). SP315–SP321. 11 indexed citations
11.
Gu, Tao, Alex Mutebi, Bradley S. Stolshek, & Hiangkiat Tan. (2018). Cost of biologic treatment persistence or switching in rheumatoid arthritis.. PubMed. 24(8 Spec No.). SP338–SP345. 13 indexed citations
12.
Horn, Leora, Joshua Bauml, Patrick M. Forde, et al.. (2018). Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 128. 74–90. 12 indexed citations
13.
14.
Harrold, Leslie R., Bradley S. Stolshek, Sabrina Rebello, et al.. (2017). Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clinical Rheumatology. 36(4). 895–901. 40 indexed citations
15.
Viswanathan, Hema N., Alex Mutebi, Cassandra E. Milmont, et al.. (2017). Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value in Health. 20(8). 1174–1179. 6 indexed citations
16.
17.
Mutebi, Alex, James Pike, Neel Shah, et al.. (2016). The Use Of Migraine Prophylaxis Treatment: Analysis Of Clinical Practice Data From The United States, Germany, France, And Japan. Value in Health. 19(3). A68–A68. 1 indexed citations
18.
Mease, Philip J., Mark C. Genovese, Alex Mutebi, et al.. (2016). Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. The Journal of Rheumatology. 43(2). 343–349. 17 indexed citations
19.
Mutebi, Alex, et al.. (2013). Assessing patients' information needs regarding drug–drug interactions. Journal of the American Pharmacists Association. 53(1). 39–45. 10 indexed citations
20.
Mutebi, Alex, John Brazier, & Stephen J. Walters. (2011). A comparison of the discriminative and evaluative properties of the SF-36 and the SF-6D index. Quality of Life Research. 20(9). 1477–1486. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pamela Church Gibson Breakdown of academic impact, for papers by Marjolaine Gauthier‐Loiselle Breakdown of academic impact, for papers by Robert C. Stuart Breakdown of academic impact, for papers by Richard M. Wolf Breakdown of academic impact, for papers by Adrienne Johnson Breakdown of academic impact, for papers by Jean Cuisenier Breakdown of academic impact, for papers by Daniela Marconi Breakdown of academic impact, for papers by Wojciech Woźniak Breakdown of academic impact, for papers by Mark Napier Breakdown of academic impact, for papers by W. Andy Knight
Rankless by CCL
2026